Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ANGN - Angion to explore strategic options after ending development of kidney disease drug

ANGN - Angion to explore strategic options after ending development of kidney disease drug

Angion Biomedica Corp.
  • Angion Biomedica ( NASDAQ: ANGN ) on Monday said it had started a process to evaluate strategic alternatives, including a merger or a sale of assets.
  • The announcement comes after the biopharmaceutical company in late June said it would discontinue its phase 2 JUNIPER trial evaluating its inhibitor ANG-3070 for the treatment of kidney diseases.
  • Angion's ( ANGN ) board approved engaging Oppenheimer & Co as the company's financial advisor to assist in the strategic alternatives process.
  • ANGN stock earlier closed -5.1% at $0.99.

For further details see:

Angion to explore strategic options after ending development of kidney disease drug
Stock Information
Company Name: Angion Biomedica Corp.
Stock Symbol: ANGN
Market: NASDAQ
Menu
ANGN ANGN Quote ANGN Short ANGN News ANGN Articles ANGN Message Board
Get ANGN Alerts

News, Short Squeeze, Breakout and More Instantly...